Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29330394 | 0.85 | KDM1A (0.39) | KDM1ASIGMAR1NPY1RHTTNPY2R | |
| SCHEMBL22473454 | 0.83 | P2RX7 (0.41) | KDM1A | |
| SCHEMBL23493304 | 0.83 | P2RX7 (0.41) | KDM1A | |
| SCHEMBL4242365 | 0.78 | OPRL1 (0.56) | OPRM1SIGMAR1NPY1RHTTNPY2R | |
| SCHEMBL24697142 | 0.75 | GBA1 (0.49) | TP53MDM2SIGMAR1NR1H2NR1H3 | |
| SCHEMBL29081820 | 0.74 | OPRM1 (0.53) | TP53MDM2OPRM1NR1H2NR1H3 | |
| SCHEMBL24364725 | 0.74 | OPRM1 (0.53) | TP53MDM2OPRM1NR1H2NR1H3 | |
| SCHEMBL2172790 | 0.72 | CHRNB2 (0.53) | TP53MDM2OPRM1HTTCYP3A4 | |
| SCHEMBL22201130 | 0.72 | CHRNB2 (0.53) | TP53MDM2OPRM1HTTCYP3A4 | |
| SCHEMBL28740375 | 0.72 | OPRL1 (0.39) | SIGMAR1TMEM97NR1H2NR1H3NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TP53 1097/4885MDM2 2080/4885OPRM1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.